Hints and tips:
...The prolonged legal battle and mounting competition in the genomics industry have caused investors to question the company’s strategy to diversify into cancer diagnostics....
...But many shareholders are sceptical about Illumina’s determination to hold on to Grail and want the board to negotiate a deal with EU authorities to spin off the cancer diagnostics company....
...executive of the world's largest genomic sequencing technology company has called for global co-operation to track new virus variants, arguing it is essential to ensure that Covid-19 vaccines, drugs, and diagnostics...
...DD’s Indap v NYU’s Damodaran: Is stock compensation good or bad?...
...Growing demand for genomic information and applications saw diagnostics company Illumina soar past analysts’ expectations in the second quarter and boost its forecast for full-year sales growth and earnings...
...Diagnostics company Illumina saw its shares climb in after-hours trading after it raised its revenue growth forecast due to stronger-than-expected demand for its NovaSeq sequencing platform and posted quarterly...
...The diagnostic group said that it expects sales in the third quarter to have risen 10 per cent on a year-on-year basis to $607m, compared with an earlier estimate of $625m – $630m....
...The S&P 500 healthcare sector posted the heaviest losses, led by the plunge in Illumina shares....
...An area where growth is more exciting is molecular diagnostics, but valuations in this field are racier — Illumina, pursued in 2013 by Swiss pharma group Roche, trades at a heady six times forecast sales...
...Meanwhile, Illumina, a diagnostics company, collapsed by a quarter and pulled the S&P 500 healthcare sector down with it....
...Illumina president Francis deSouza says better diagnostics can save lives and money. “Treating cancer at stage one is much cheaper than treating it late.”...
...“Cambridge Epigenetix is ideally positioned to catalyse the market for epigenetics, just as Solexa and Illumina did for genomics a decade ago,” adds Dr Smith, who joined the company from Illumina where he...
...They must be visionaries and business strategists at the same time, balancing the demands of basic research with more commercial undertakings such as developing diagnostic kits and tests....
...Meanwhile, Astra said it had teamed up with US diagnostics group Illumina to develop a gene-sequencing platform it believes will speed up clinical trials for cancer treatments....
...Earlier this month it announced a collaboration with US diagnostics company Illumina to develop a gene-sequencing platform it believes will speed up clinical trials for cancer treatments....
...Last month, Roche, which predicts a big role for gene sequencing in its large diagnostics business, bought Genia, a privately owned Californian sequencing company, in a deal worth up to $350m....
...Roche on Thursday made its long-expected improved cash offer for Illumina with a 15 per cent increase to $51 a share, valuing the US diagnostics group at about $6.7bn ....
...Some Illumina shareholders are already backing Roche. If Mr Flatley and the board are too intractable, Illumina’s share price has a long way to fall....
...Roche on Thursday sent its third letter to Illumina shareholders, repeating its readiness to improve its takeover offer, as strong diagnostic sales in the first quarter reflected the Swiss pharmaceuticals...
...He warned that Illumina alone did not have the scale and infrastructure to expand successfully in diagnostics and had little experience in regulated areas....
...Mr Funtleyder said gene sequencing had the potential to be a “game changer” in diagnostics and personalised medicine and that Illumina did not want to be swallowed up by the larger Roche and lose its identity...
...The US diagnostics company Illumina has rejected Roche’s $5.7bn hostile takeover bid, calling the offer “grossly inadequate” and urging stockholders not to tender their shares....
...The chief executive of Illumina, the US genetic diagnostic company, has implemented a “poison pill” to try to frighten off Roche, the Swiss drugmaker, that this week went hostile in its bid for the company...
...The change of fortunes came as the group stepped up its $5.7bn hostile bid for Illumina, the US manufacturer of genetic testing equipment, by announcing it has proposed a slate of new Illumina directors...
International Edition